T Cell Engineering and the Rise of CAR-T Cell Therapies

Author(s):  
Benjamin Philipson ◽  
Michael C. Milone
2019 ◽  
Vol 15 (5) ◽  
pp. 619-636 ◽  
Author(s):  
Safa Tahmasebi ◽  
Reza Elahi ◽  
Abdolreza Esmaeilzadeh

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Ruihao Huang ◽  
Xiaoping Li ◽  
Yundi He ◽  
Wen Zhu ◽  
Lei Gao ◽  
...  

Nano Letters ◽  
2020 ◽  
Vol 20 (3) ◽  
pp. 1578-1589 ◽  
Author(s):  
Margaret M. Billingsley ◽  
Nathan Singh ◽  
Pranali Ravikumar ◽  
Rui Zhang ◽  
Carl H. June ◽  
...  

2020 ◽  
Vol 12 (574) ◽  
pp. eabg0485

Four times a year, the Science Translational Medicine editors select recently published articles across the Science family of journals and highlight interesting translational ties. These short write-ups identify common links between disparate diseases; technologies and research approaches that could prove complementary; and biomedical insights that may inform therapies or treatments. This quarter’s articles cover flexible biosensors, SARS-CoV-2 transmission from a genomics perspective, advances in CAR T cell engineering, the intestinal microbiome, the host immune response to SARS-CoV-2, and strategies for treating infectious diseases.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Noah H. Richardson ◽  
Jordan B. Luttrell ◽  
Jonathan S. Bryant ◽  
Damian Chamberlain ◽  
Saleem Khawaja ◽  
...  

Abstract Background Simultaneous advances in gene editing, T cell engineering and biotechnology currently provide an opportunity for rapid progress in medicine. The approval of chimeric antigen receptor (CAR) T cell therapies by the US Food and Drug Administration (FDA) and the European Commission have generated substantial momentum for these first-in-class therapies to be used in patients with B cell malignancies. Main body Considerable efforts focus on improved outcomes and reduced side effects of the newly approved therapies. Using innovative strategies, researchers aim to extend CAR T cell use to tackle difficulties inherent in solid tumors. Efforts are underway to broaden the applications of CAR T cells, and the strategy has been successful in chronic viral infections and preclinical models of autoimmunity. Research is in progress to generate “off-the-shelf” CAR T cells, an advance, which would greatly increase patient availability and reduce treatment cost. Conclusions In this thematic review, we highlight advances that may help develop genetically engineered cells into a new category of medical therapies.


Leukemia ◽  
2016 ◽  
Vol 31 (1) ◽  
pp. 186-194 ◽  
Author(s):  
R Monjezi ◽  
C Miskey ◽  
T Gogishvili ◽  
M Schleef ◽  
M Schmeer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document